Service area · Pharmaceutical policy
tiger.PHARMA combines current regulatory changes, supply and market data, and operational consequences into decision-ready pharmaceutical analysis for Germany and Europe.
Analyse a pharmaceutical decision question →
Pharma market · regulation · scenarios · decision brief
tiger.PHARMA combines current regulatory changes, supply and market data, and operational consequences into decision-ready pharmaceutical analysis for Germany and Europe.
The analysis separates applicable law, adopted changes, drafts, observable market signals and internal assumptions. The EU pharmaceutical package, AMNOG and early benefit assessment, shortages, market access and the supply chain are therefore not presented as a news list but as concrete decision questions with source, data date, scenario and accountable follow-up. Binding legal assessments remain with authorised legal advisers and competent authorities.
tiger.PHARMA Expertise
Every analysis starts with a specific management decision rather than an open-ended collection of material. Product, market, period, organisational units and decision deadline are defined.
Regulatory signals are separated into applicable law, adopted change, draft, consultation and professional expectation. Every statement carries a source, cut-off date, affected function and next review date.
The reform of European pharmaceutical legislation is translated into the specific product and organisational question. Only genuinely relevant changes are analysed, for example authorisation, shortage prevention, environmental provisions or incentives.
For Germany, authorisation, early benefit assessment, price and reimbursement logic, and commercial implementation are treated as separate but interdependent decisions.
Public shortage information is connected with product criticality, sources of supply, replenishment time, inventory and operational alternatives. A reported unavailability is not automatically represented as the organisation's own supply status.
Signals are converted into at least a base, risk and alternative-action scenario. Effects, occurrence drivers, reversibility and early indicators remain traceable.
The result is a concise decision document with a source annex and action register. Management, specialist functions and external advisers can see what is confirmed, uncertain or still to be examined.
FAQ
It classifies regulatory developments by status, cut-off date, affected products and functions and converts them into concrete decision and review tasks. Draft, adoption and applicable law remain distinct.
Official primary sources from competent European and German institutions take priority. Secondary sources provide orientation only and never replace checking the official text.
No. tiger.PHARMA provides pharmaceutical, market and operational interpretation. Binding legal assessments and contractual questions remain with authorised legal advisers and authorities.
Uncertainty is labelled as an assumption or scenario. Triggers, observation points, data date and next review are documented; no falsely precise forecast is presented.
Yes, where this is relevant to the specific product decision. European authorisation and supply rules and German benefit assessment and reimbursement remain distinct procedures with explicit interfaces.
A concise decision brief, source and status register, scenarios, an action register with accountable owners and a defined review date.